Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.037 | 0.7 |
mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | Epothilone B | FIMM | pan-cancer | AAC | -0.056 | 0.7 |
mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |